Pyoderma gangrenosum: A review and update on new therapies
Pyoderma gangrenosum is a rare and often painful skin disease that can be unpredictable in its response to treatment. There is currently no gold standard of treatment or published algorithm for choice of therapy. The majority of data comes from case studies that lack a standard protocol not only for treatment administration but also for the objective assessment of lesion response to a specific therapy. This review provides an update to the treatment of pyoderma gangrenosum with a particular focus on new systemic therapies.
aDepartment of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina
bDepartment of Pathology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina
cDepartment of Public Health Sciences, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Correspondence to: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071.
Astellas Pharma Global Development Inc provided support for the preparation of this review. The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories LP.
Disclosure: Dr Feldman has received research, speaking, and/or consulting support from Abbott Labs, American Society for Dermatologic Surgery, Amgen, Astellas, Aventis Pharmaceuticals, Biogen, Centocor, Connetics, Galderma, Genentech, Novartis, and Roche. Dr Jorizzo has received speaking and/or consulting support from Amgen. Dr Miller, Dr Yentzer, and Ms Clark have no conflicts of interest to declare.
ABSTRACT